Imodium

Loperamide Hydrochloride, the active ingredient in Imodium, is an antidiarrheal presented as an oral tablet for oral use. It reduces the frequency of watery stools in acute nonspecific diarrhea, chronic diarrhea linked to inflammatory bowel disease, and irritable bowel syndrome with diarrhea, and is used in adults and older children as directed by a health professional.

GNH USA supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium acts on the gastrointestinal tract to control excess stool output in several diarrheal conditions.

Acute nonspecific diarrhea: reduces stool frequency and improves consistency. Chronic diarrhea associated with inflammatory bowel disease: helps maintain stool form and reduces urgency. Irritable bowel syndrome with diarrhea: alleviates loose stools and abdominal urgency.

Adverse reactions may range from mild to severe, depending on individual susceptibility and dosage.

Common Side Effects: - Constipation - Abdominal cramping - Nausea - Dry mouth - Dizziness - Headache

Serious or Rare Side Effects: - Severe constipation or bowel obstruction - Toxic megacolon - Allergic reactions such as rash or itching - Cardiac arrhythmias (QT prolongation) - Ileus - Urinary retention

Use Imodium according to professional guidance and be aware of specific safety considerations. - Do not exceed the recommended dose: follow prescriber or label instructions. - Use caution in patients with hepatic impairment: dose adjustment may be needed. - Avoid in children under two years unless specifically directed by a clinician. - Monitor for signs of constipation: discontinue if severe. - Store at room temperature: keep in the original pack, protect from moisture.

Loperamide can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase loperamide levels. - Other antidiarrheal agents (e.g., diphenoxylate): additive effect on gut motility. - QT‑prolonging drugs (e.g., quinidine): heightened risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil): may modestly raise plasma concentrations. - Opioid analgesics: potential for enhanced central opioid effects. - Anticholinergic medications: increased risk of constipation.